Invesco Ltd. Purchases 1,292,399 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Invesco Ltd. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 11,277,915 shares of the biopharmaceutical company's stock after buying an additional 1,292,399 shares during the period. Invesco Ltd. owned approximately 0.90% of Gilead Sciences worth $1,041,741,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust purchased a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $105.12.

Remove Ads

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.95 during trading on Thursday, reaching $102.30. The stock had a trading volume of 7,458,154 shares, compared to its average volume of 7,461,123. The stock has a market cap of $127.38 billion, a PE ratio of 274.61, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm's 50 day moving average price is $108.17 and its two-hundred day moving average price is $96.52. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 302,785 shares of company stock worth $30,503,250. Insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.